Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Immunotherapy

Posts tagged ‘JNJ–64619178’

An unexpected surprise!

Time for a fishing expedition or two

In our fifth preview from the AACR annual meeting being held in San Diego next month, we noticed some intriguing surprises emerging from one class of agents currently being studied both preclinically, as well as in the clinic.

What are they – and why do they matter?

Quite simply, once the implications are understood they may help us understand where the field is headed in the near to medium term – and why some particular combinations might yield some interesting findings…

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Dancing with Cancer Cells

Spotting the Baubles amongst the Glitter

Readers in the UK who follow the BBC show ‘Strictly Come Dancing’ will know this Saturday night the show returns to the iconic Tower Ballroom in Blackpool.  All the contestants wanted to make it to this stage of the competition.

To put this analogy in context, an oncology equivalent might be the prestige of giving an oral presentation at a major medical meeting, it’s something you definitely remember and want to do!

There are many metaphors related to dancing that can apply to cancer research e.g. we’ve heard one leading researcher describe how immune cells and cancer cells ‘dance’ together.  As they say, it takes two to tango…

How new products ’embrace’ and interact with cancer cells, their receptors and binding sites can be key to therapeutic success. There are a variety of ways to do this, one of which can lead to cancer cell death via synthetic lethality, a concept we’ve covered extensively over many years going back to the emergence of PARP inhibitors in 2006.

In this post, we’re taking a closer look at an emerging biotech company, their drug discovery pipeline, and some innovative targets that may enable their new drugs to better ‘dance’ with cancer cells in a way that interrupts their routine, and ultimately, leads to their death.

Keep on dancing!

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Highlights from Mini Oral Sessions at ESMO20

Not in Madrid: The 2020 virtual congress of the European Society for Medical Oncology (#ESMO20) is underway and in this post we’re taking a look at some of the highlights from Friday at ESMO20, a day when we’ve seen a raft of posters and mini-orals released for on-demand viewing.

ESMO20 BannerWith COVID-19 rates rising across Europe, ESMO are to be congratulated for pivoting to a virtual meeting that allows the sharing of knowledge and advancement of the field. It was definitely the right decision in light of the ongoing travel challenges, quarantines, not to mention restrictions on large groups in many countries.

For our daily ESMO20 coverage – just as we would if we had been in Madrid – we’ve been listening to some of the on-demand mini-oral presentations and associated discussions, with a view to picking out and commenting on a few that stood out for us.

As always we’re approaching this from a cancer new product development perspective, and our choice is always a balance of emerging new targets and drugs, as well as following those we’ve previously written about.

To learn more from our oncology analysis and get a heads up on insights and commentary pertaining to ESMO 2020, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

ESMO20 Preview 2 – New Targets, New Opportunities

Sunset in Puerta del Sol, Madrid

Not in Madrido – In our latest ESMO20 Preview, we take a look at five emerging areas of cancer drug development involving early stage pipelines and highlight some important features and benefits to watch out for.

These topics won’t be on everyone’s radar, especially if the focus is on the big phase 3 trial readouts, yet they can teach us much about new combinations and future pipeline evolution.

Who’s actively moving novel approaches along and who’s sitting on their laurels?

After covering biomarkers to watch out for yesterday, we now take a dive into what’s looking interesting in terms of novel targets and the fresh new opportunities for the not faint of heart…

To learn more from our oncology analysis and get a heads up on insights and commentary pertaining to ESMO 2020, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

A new dawn for epigenetic therapy in oncology

A new dawn or a rapid sunset for epigenetics in oncology R&D?

Epigenetic therapies have had somewhat of a chequered history in oncology R&D, but new targets are always cropping up to tempt us to look further.

One emerging target we’ve come across – this is only the fourth mention here since January 2019 – is starting to gather steam with new players entering the landscape, as well as emerging preclinical and clinical evidence suggesting it might be well worth a serious look.

Here we look at the potential role this epigenetic target may have to play in a variety of difficult to treat cancers, as well as how it could enhance existing therapies in new combination approaches.

Could we combine these inhibitors with chemotherapy, with immunotherapy or DNA repair approaches?  How does the therapeutic window stack up?

We look at the latest evidence from several sources and discuss where the opportunities might lie…

To learn more from our oncology analysis and get a heads up on insights and commentary an emerging area of epigenetics, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

error: Content is protected !!